$ELOX
Eloxx Pharmaceuticals, Inc.

2013 Q4 Form 10-Q Financial Statement

#000114420413061794 Filed on November 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $0.00 $100.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $860.0K $860.0K $670.0K
YoY Change 34.38% 28.36% 13.56%
% of Gross Profit
Research & Development $730.8K $810.9K $513.4K
YoY Change 23.64% 57.94% -19.04%
% of Gross Profit
Depreciation & Amortization $80.00K $70.00K $60.00K
YoY Change 14.29% 16.67% 0.0%
% of Gross Profit
Operating Expenses $730.8K $810.9K $513.4K
YoY Change 23.64% 57.94% -19.04%
Operating Profit -$1.589M -$1.753M -$1.246M
YoY Change 22.22% 40.65% -2.66%
Interest Expense -$30.73K -$31.60K -$33.98K
YoY Change -10.35% -7.0% 11.27%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$1.620M -$1.780M -$2.090M
YoY Change 27.56% -14.83% 100.96%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.620M -$1.784M -$2.085M
YoY Change 27.54% -14.44% 100.72%
Net Earnings / Revenue -1784.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.529M -$14.83M -$41.80M
COMMON SHARES
Basic Shares Outstanding 231.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.120M $790.0K $1.310M
YoY Change 856.25% -39.69% -53.87%
Cash & Equivalents $6.122M $789.2K $1.312M
Short-Term Investments
Other Short-Term Assets $1.490M $1.570M $1.460M
YoY Change 14.62% 7.53% -19.78%
Inventory
Prepaid Expenses $1.488M $1.567M $1.460M
Receivables
Other Receivables
Total Short-Term Assets $7.610M $2.356M $2.772M
YoY Change 292.29% -15.01% -40.65%
LONG-TERM ASSETS
Property, Plant & Equipment $3.512K $4.032K $6.491K
YoY Change -64.88% -37.88%
Goodwill
YoY Change
Intangibles $3.482M $3.450M $3.477M
YoY Change -0.77%
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $3.491M $3.459M $3.488M
YoY Change -0.82% -0.84% -3.1%
TOTAL ASSETS
Total Short-Term Assets $7.610M $2.356M $2.772M
Total Long-Term Assets $3.491M $3.459M $3.488M
Total Assets $11.10M $5.815M $6.260M
YoY Change 103.32% -7.11% -24.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $477.6K $1.004M $932.2K
YoY Change -56.18% 7.69% -1.88%
Accrued Expenses $616.9K $406.8K $305.0K
YoY Change 31.26% 33.38% -53.08%
Deferred Revenue
YoY Change
Short-Term Debt $2.190M $2.190M $2.200M
YoY Change -0.45% -0.45% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.282M $3.598M $3.436M
YoY Change -12.49% 4.7% -9.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $99.73K $99.73K $99.73K
YoY Change -23.29% 0.0% -81.53%
Total Long-Term Liabilities $99.73K $99.73K $99.73K
YoY Change -23.29% 0.0% -81.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.282M $3.598M $3.436M
Total Long-Term Liabilities $99.73K $99.73K $99.73K
Total Liabilities $3.381M $3.697M $3.631M
YoY Change -12.85% 1.84% -16.34%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $49.57K $23.48K $1.168M
YoY Change -97.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.720M $2.117M $2.629M
YoY Change
Total Liabilities & Shareholders Equity $11.10M $5.815M $6.260M
YoY Change 103.32% -7.11% -24.3%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$1.620M -$1.784M -$2.085M
YoY Change 27.54% -14.44% 100.72%
Depreciation, Depletion And Amortization $80.00K $70.00K $60.00K
YoY Change 14.29% 16.67% 0.0%
Cash From Operating Activities -$1.420M -$670.5K -$636.5K
YoY Change 153.57% 5.34% -41.62%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K $0.00 $1.281K
YoY Change 10.0% -100.0% -100.99%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$110.0K -$142.9K -$147.0K
YoY Change 10.0% -2.76% 14.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.505M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.870M $290.00 $94.18K
YoY Change -99.69% -79.12%
NET CHANGE
Cash From Operating Activities -1.420M -$670.5K -$636.5K
Cash From Investing Activities -110.0K -$142.9K -$147.0K
Cash From Financing Activities 6.870M $290.00 $94.18K
Net Change In Cash 5.340M -$813.1K -$689.3K
YoY Change -909.09% 17.97% -10.25%
FREE CASH FLOW
Cash From Operating Activities -$1.420M -$670.5K -$636.5K
Capital Expenditures -$110.0K $0.00 $1.281K
Free Cash Flow -$1.310M -$670.5K -$637.7K
YoY Change 184.78% 5.13% -33.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5171 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1602294 USD
CY2013Q2 us-gaap Assets
Assets
7097737 USD
CY2013Q3 us-gaap Liabilities
Liabilities
3697413 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
406779 USD
CY2013Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5171 USD
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
789176 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1003824 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
637320 USD
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728 USD
CY2013Q2 us-gaap Liabilities
Liabilities
3311670 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
387540 USD
CY2013Q3 us-gaap Assets
Assets
5814903 USD
CY2013Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3566497 USD
CY2013Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2187082 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
74425835 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7097737 USD
CY2012Q3 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
940449 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
732720 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
727119 USD
CY2013Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
185161 USD
CY2012Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
1852729 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
1246153 USD
us-gaap Costs And Expenses
CostsAndExpenses
61262735 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1752729 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1246153 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-59372735 USD
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
244479 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
8701721 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3211942 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3597685 USD
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
100000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35054750 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
513433 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24049390 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
0 USD
CY2012Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-20148 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4555 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
3521514 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
23482 USD
CY2013Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1566515 USD
CY2013Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1919220 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
2355691 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4032 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
22721 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
78325793 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
78189173 USD
CY2013Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
76231791 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
2117490 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
3786067 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5814903 USD
us-gaap Licenses Revenue
LicensesRevenue
1890000 USD
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3450009 USD
CY2013Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2187082 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2158595 USD
us-gaap Net Income Loss
NetIncomeLoss
-64843629 USD
CY2012Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1805956 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2709623 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76231791 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
CY2013Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0 USD
CY2012Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0 USD
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
586442 USD
CY2013Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2012Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
205390 USD
CY2013Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2012Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-785171 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1724546 USD
CY2013Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2012Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-361877 USD
CY2013Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
CY2012Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11227870 USD
CY2013Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2012Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
2027930 USD
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-31604 USD
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33982 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
133297 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1784333 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2085454 USD
CY2013Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
21623 USD
CY2012Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
624169 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
11388162 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1805956 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2709623 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76231791 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2307926 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1074493 shares
CY2013Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
124466 USD
CY2013Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2013Q3 us-gaap Dividends
Dividends
9000 USD
CY2013Q3 us-gaap Noncash Contribution Expense
NoncashContributionExpense
0 USD
CY2012Q3 us-gaap Noncash Contribution Expense
NoncashContributionExpense
0 USD
us-gaap Noncash Contribution Expense
NoncashContributionExpense
85179 USD
CY2013Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
CY2012Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
131250 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
CY2012Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-20148 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
9022980 USD
CY2013Q3 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2012Q3 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
115869 USD
CY2013Q3 us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53800 USD
CY2010Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
3000000 USD
CY2010Q1 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0375 pure
CY2012Q3 us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
2003386 USD
CY2013Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2012Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2010Q1 snti Line Of Credit Spread Over Base Rate
LineOfCreditSpreadOverBaseRate
0.020 pure
CY2013Q3 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2187082 USD
CY2013Q2 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2187082 USD
CY2013Q3 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
32197 USD
CY2012Q3 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
34990 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000000 USD
CY2013Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2012Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1227869 USD
CY2013Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
789176 USD
CY2013Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1602294 USD
CY2012Q3 snti Gain Loss On Settlement Of Warrant Liabilities
GainLossOnSettlementOfWarrantLiabilities
-785171 USD
snti Gain Loss On Settlement Of Warrant Liabilities
GainLossOnSettlementOfWarrantLiabilities
-1724546 USD
CY2013Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-352705 USD
CY2012Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-88881 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1566515 USD
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
124466 USD
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
153562 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12955112 USD
CY2013Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
74793 USD
CY2012Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
63572 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1468727 USD
CY2013Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2013Q3 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
CY2012Q3 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
5171 USD
CY2013Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
366504 USD
CY2012Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
337653 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1003824 USD
CY2013Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10239 USD
CY2012Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
552780 USD
CY2013Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-670465 USD
CY2012Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-636454 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41595481 USD
CY2013Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
142943 USD
CY2012Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
145717 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6895416 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
185947 USD
CY2013Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-142943 USD
CY2012Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146998 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7081363 USD
CY2013Q3 snti Proceeds From Government Grant
ProceedsFromGovernmentGrant
0 USD
CY2012Q3 snti Proceeds From Government Grant
ProceedsFromGovernmentGrant
0 USD
snti Proceeds From Government Grant
ProceedsFromGovernmentGrant
99728 USD
CY2013Q3 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
CY2012Q3 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
2187082 USD
CY2013Q3 snti Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
0 USD
CY2012Q3 snti Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
0 USD
snti Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
10754841 USD
CY2013Q3 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
CY2012Q3 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2160986 USD
CY2013Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2012Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
651781 USD
CY2013Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
290 USD
CY2012Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
94183 USD
CY2013Q3 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in; TEXT-INDENT: 0in" align="left"><b><font style="FONT-SIZE: 10pt">Note 1 - Basis of Presentation:</font></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The financial statements included herein have been prepared by Senesco Technologies, Inc. (the &#8220;Company&#8221;), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, as amended.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s board of directors authorized a 1:100 reverse stock split on September 30, 2013, to take effect on October 21, 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> All share and related option and warrant information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the reduced number of shares resulting from this action.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of September 30, 2013 and the results of its operations and cash flows for the three months ended September 30, 2013 and 2012.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Interim results are not necessarily indicative of results for the full fiscal year.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2012Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1281 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
29372136 USD
CY2013Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
290 USD
CY2012Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94183 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49466020 USD
CY2013Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-813118 USD
CY2012Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-689269 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
604015 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2001325 USD
CY1998Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1312056 USD
CY2013Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1505000 USD
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P17Y
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
74270 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62925 USD
CY2013Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
73331 USD
CY2012Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
137810 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
495253 USD
CY2013Q3 snti Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
0 USD
CY2012Q3 snti Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
0 USD
snti Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
690984 USD
CY2013Q3 snti Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
9000 USD
CY2012Q3 snti Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
-64722 USD
snti Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
143474 USD
CY2013Q3 us-gaap Interest Paid
InterestPaid
32197 USD
CY2012Q3 us-gaap Interest Paid
InterestPaid
34990 USD
us-gaap Interest Paid
InterestPaid
526334 USD
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 snti Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock
CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock
193333 shares
CY2012Q3 snti Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock
CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock
38269 shares
CY2013Q3 snti Number Of Diluted Warrants Outstanding
NumberOfDilutedWarrantsOutstanding
282866 shares
CY2012Q3 snti Number Of Diluted Warrants Outstanding
NumberOfDilutedWarrantsOutstanding
400968 shares
CY2013Q3 snti Number Of Diluted Options Outstanding
NumberOfDilutedOptionsOutstanding
277240 shares
CY2012Q3 snti Number Of Diluted Options Outstanding
NumberOfDilutedOptionsOutstanding
156477 shares
CY2013Q3 snti Potential Dilutive Shares Of Common Stock
PotentialDilutiveSharesOfCommonStock
753440 shares
CY2012Q3 snti Potential Dilutive Shares Of Common Stock
PotentialDilutiveSharesOfCommonStock
595715 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2348209 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2348209 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2272062 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2272062 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
46780 shares
CY2013Q3 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
201154 USD
CY2013Q3 snti Probability To Achieve Employee Target Goals
ProbabilityToAchieveEmployeeTargetGoals
0.41 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
811 shares
CY2013Q3 snti Unrecognized Share Based Compensation Expense
UnrecognizedShareBasedCompensationExpense
762000 USD
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P47Y6M
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
231748 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
73280 shares
CY2013Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2013Q3 snti Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
-27788 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
277240 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
185031 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.23
CY2013Q3 snti Share Based Compensation Shares Authorized Under Stock Option Plans Granted Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantedExercisePrice
5.40
CY2013Q3 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePrice
0
CY2013Q3 snti Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePrice
16.50
CY2013Q3 snti Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePrice
0
CY2013Q3 snti Issuance Of Additional Options
IssuanceOfAdditionalOptions
26500 shares
CY2013Q3 snti Options Aggregated During Period
OptionsAggregatedDuringPeriod
108650 USD
CY2013Q3 snti Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedPercentage
0.75 pure
CY2013Q3 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
9100 USD
CY2013Q3 snti Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
290 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.99 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0165 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0196 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2013Q3 snti Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable And Expected To Be Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndExpectedToBeExercisableNumber
262795 shares
CY2013Q2 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit
4.30
CY2013Q3 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit
4.30
CY2013Q2 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit
345.00
CY2013Q3 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit
345.00
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.00
CY2013Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.40
CY2013Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2013Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.50
CY2013Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.30
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.37
CY2013Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2010Q1 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Line of Credit accrue at an annual interest rate of (i) the broker rate in effect at the interest date (which was 3.75% at September 30, 2013), plus (ii) 2.0% and are due on demand. There are no other conditions or fees associated with the Line of Credit.

Files In Submission

Name View Source Status
0001144204-13-061794-index-headers.html Edgar Link pending
0001144204-13-061794-index.html Edgar Link pending
0001144204-13-061794.txt Edgar Link pending
0001144204-13-061794-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snti-20130930.xml Edgar Link completed
snti-20130930.xsd Edgar Link pending
snti-20130930_cal.xml Edgar Link unprocessable
snti-20130930_def.xml Edgar Link unprocessable
snti-20130930_lab.xml Edgar Link unprocessable
snti-20130930_pre.xml Edgar Link unprocessable
v358384_10q.htm Edgar Link pending
v358384_ex31-1.htm Edgar Link pending
v358384_ex31-2.htm Edgar Link pending
v358384_ex32-1.htm Edgar Link pending
v358384_ex32-2.htm Edgar Link pending